Teruo Shiba
Overview
Explore the profile of Teruo Shiba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki Y, Shiba T
Int J Hematol
. 2022 Oct;
117(4):618-621.
PMID: 36309629
COVID-19 mRNA vaccines manufactured by Pfizer-BioNTech and Moderna have been approved in many countries, and have been administered since 2020. Recent reports of mRNA vaccination exacerbating autoimmune hematologic disorders, such...
2.
Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al.
Int J Cardiol
. 2020 Jan;
305:139-146.
PMID: 31987664
Background: There has been no report about outcome of pitavastatin versus atorvastatin therapy in high-risk patients with hypercholesterolemia. Methods: Hypercholesterolemic patients with one or more risk factors for atherosclerotic diseases...
3.
Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Noso S, Ikegami H, et al.
Endocr J
. 2019 Mar;
66(4):295-300.
PMID: 30814440
Therapeutic blocking antibodies against programmed death 1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are applied for advanced cancer therapy, but induce a wide range of immune-related adverse events. In...
4.
Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Tanaka S, Shiba T
Diabetes Obes Metab
. 2018 Aug;
21(2):388-392.
PMID: 30146790
Aim: To elucidate the mechanisms involved in the sequential use of SGLT2 and DPP4 inhibitors (SGLT2i and DPP-4i). Methods: Twenty-six type-2 diabetes mellitus patients were recruited into a stepped regimen...
5.
Shiba T, Ishii S, Okamura T, Mitsuyoshi R, Pfarr E, Koiwai K
Diabetes Res Clin Pract
. 2017 Jul;
131:169-178.
PMID: 28753486
Aims: To investigate the efficacy and safety of empagliflozin in subgroups based on body mass index (BMI) and age, using a pooled data set from Japanese patients with type 2...
6.
Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, et al.
Lipids Health Dis
. 2017 Jun;
16(1):122.
PMID: 28646901
Background: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with...
7.
Sakamoto K, Kawamura M, Kohro T, Omura M, Watanabe T, Ashidate K, et al.
PLoS One
. 2015 Sep;
10(9):e0138332.
PMID: 26398887
Background: There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on...
8.
Obata A, Kaneto H, Kamei S, Shimoda M, Kishi S, Isogawa A, et al.
Diabetes Care
. 2015 Jun;
38(9):e135-6.
PMID: 26116721
No abstract available.
9.
Shiba T
Nihon Rinsho
. 2015 Mar;
73(3):438-46.
PMID: 25812370
SGLT2 is a low affinity, high capacity glucose co-transporter, almost exclusively expressed in the kidney cortex. Inhibition of SGLT2 has been shown to increase the daily 50g or more urinary...
10.
Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, et al.
Lipids Health Dis
. 2013 Oct;
12:142.
PMID: 24094079
Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins...